Recent Advances in Understanding and Managing Tourette Syndrome

F1000Research

Volumn 5, Issue , 2016, Pages

  Jankovic, Joseph ^a   Thenganatt, Mary Ann ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; BOTULINUM TOXIN; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; TETRABENAZINE;

BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; COPY NUMBER VARIATION; CYTOGENETICS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; GILLES DE LA TOURETTE SYNDROME; HUMAN; LINKAGE ANALYSIS; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84964414255     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7424.1     Document Type: Review

References (74)

1. Jankovic J Gelineau-Kattner R Davidson A: Tourette's syndrome in adults. Mov Disord. 2010;25(13):2171-2175. 20690167 10.1002/mds.23199
2. Patel N Jankovic J Hallett M: Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100-112. 24331796 10.1016/S1474-4422(13)70213-8
3. Baizabal-Carvallo JF Jankovic J: Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015;262(11):2420-2424. 26194199 10.1007/s00415-015-7856-7
4. Thenganatt MA Jankovic J: Psychogenic movement disorders. Neurol Clin. 2015;33(1):205-224. 25432730 10.1016/j.ncl.2014.09.013
5. Baizabal-Carvallo JF Jankovic J: The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014;85(5):573-575. 24259592 10.1136/jnnp-2013-305594
6. Association AP: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Publishing;2013. 10.1176/appi.books.9780890425596
7. Scharf JM Miller LL Gauvin CA: Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30(2):221-228. 25487709 10.1002/mds.26089 F1000 Recommendation
8. Hirschtritt ME Lee PC Pauls DL: Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA psychiatry. 2015;72(4):325-333. 25671412 10.1001/jamapsychiatry.2014.2650 4446055 F1000 Recommendation
9. Worbe Y Lehericy S Hartmann A: Neuroimaging of tic genesis: Present status and future perspectives. Mov Disord. 2015;30(9):1179-1183. 26377151 10.1002/mds.26333
10. Black KJ Jankovic J Hershey T: Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord. 2014;3(4):359-362. 25436182 10.1016/j.jocrd.2014.03.005 4243166
11. Muellner J Delmaire C Valabra R: Altered structure of cortical sulci in gilles de la Tourette syndrome: Further support for abnormal brain development. Mov Disord. 2015;30(5):655-661. 25820811 10.1002/mds.26207
12. Martín-Rodríguez JF Ruiz-Rodríguez MA Palomar FJ: Aberrant cortical associative plasticity associated with severe adult Tourette syndrome. Mov Disord. 2015;30(3):431-435. 25649686 10.1002/mds.26151
13. Suppa A Marsili L Di Stasio F: Cortical and brainstem plasticity in Tourette syndrome and obsessive-compulsive disorder. Mov Disord. 2014;29(12):1523-1531. 24996148 10.1002/mds.25960
14. Worbe Y Marrakchi-Kacem L Lecomte S: Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome. Brain. 2015;138(Pt 2):472-482. 25392196 10.1093/brain/awu311 4306818 F1000 Recommendation
15. Yael D Vinner E Bar-Gad I: Pathophysiology of tic disorders. Mov Disord. 2015;30(9):1171-1178. 26179434 10.1002/mds.26304
16. Neuner I Werner CJ Arrubla J: Imaging the where and when of tic generation and resting state networks in adult Tourette patients. Front Hum Neurosci. 2014;8:362. 24904391 10.3389/fnhum.2014.00362 4035756 F1000 Recommendation
17. Tinaz S Belluscio BA Malone P: Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging. Hum Brain Mapp. 2014;35(12):5834-5846. 25044024 10.1002/hbm.22588 F1000 Recommendation
18. Cheng B Braass H Ganos C: Altered intrahemispheric structural connectivity in Gilles de la Tourette syndrome. Neuroimage Clin. 2014;4:174-181. 24371800 10.1016/j.nicl.2013.11.011 3872720 F1000 Recommendation
19. Lerner A Bagic A Simmons JM: Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain. 2012;135(Pt 6):1926-1936. 22577221 10.1093/brain/aws104 3359755 F1000 Recommendation
20. Kataoka Y Kalanithi PS Grantz H: Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol. 2010;518(3):277-291. 19941350 10.1002/cne.22206 2846837 F1000 Recommendation
21. Tinaz S Malone P Hallett M: Role of the right dorsal anterior insula in the urge to tic in Tourette syndrome. Mov Disord. 2015;30(9):1190-1197. 25855089 10.1002/mds.26230 F1000 Recommendation
22. Hanna PA Janjua FN Contant CF: Bilineal transmission in Tourette syndrome. Neurology. 1999;53(4):813-818. 10489047 10.1212/WNL.53.4.813
23. Pauls DL Fernandez TV Mathews CA: The Inheritance of Tourette Disorder: A review. J Obsessive Compuls Relat Disord. 2014;3(4):380-385. 25506544 10.1016/j.jocrd.2014.06.003 4260404
24. Mataix-Cols D Isomura K Perez-Vigil A: Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study. JAMA psychiatry. 2015;72(8):787-793. 26083307 10.1001/jamapsychiatry.2015.0627 F1000 Recommendation
25. Deng H Gao K Jankovic J: The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8(4):203-213. 22410579 10.1038/nrneurol.2012.26
26. Ercan-Sencicek AG Stillman AA Ghosh AK: L-histidine decarboxylase and Tourette's syndrome. N Engl J Med. 2010;362(20):1901-1908. 20445167 10.1056/NEJMoa0907006 2894694
27. Karagiannidis I Dehning S Sandor P: Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet. 2013;50(11):760-764. 23825391 10.1136/jmedgenet-2013-101637
28. Scharf JM Yu D Mathews CA: Genome-wide association study of Tourette's syndrome. Mol Psychiatry. 2013;18(6):721-728. 22889924 10.1038/mp.2012.69 3605224
29. Paschou P Yu D Gerber G: Genetic association signal near NTN4 in Tourette syndrome. Ann Neurol. 2014;76(2):310-315. 25042818 10.1002/ana.24215 4140987
30. McGrath LM Yu D Marshall C: Copy number variation in obsessive-compulsive disorder and Tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014;53(8):910-919. 25062598 10.1016/j.jaac.2014.04.022 4218748
31. Yu D Mathews CA Scharf JM: Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015;172(1):82-93. 25158072 10.1176/appi.ajp.2014.13101306 4282594
32. Albin RL Koeppe RA Wernette K: Striatal [ 11C]dihydrotetrabenazine and [ 11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72(16):1390-1396. 19380698 10.1212/WNL.0b013e3181a187dd 2677509
33. Termine C Selvini C Rossi G: Emerging treatment strategies in Tourette syndrome: what's in the pipeline? Int Rev Neurobiol. 2013;112:445-480. 24295630 10.1016/B978-0-12-411546-0.00015-9
34. Jankovic J: Therapeutic developments for tics and myoclonus. Mov Disord. 2015;30(11):1566-1573. 26315614 10.1002/mds.26414
35. Mogwitz S Buse J Ehrlich S: Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome. Int Rev Neurobiol. 2013;112:281-349. 24295625 10.1016/B978-0-12-411546-0.00010-X
36. Wijemanne S Wu LJ Jankovic J: Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126-130. 24150997 10.1002/mds.25692
37. Weisman H Qureshi IA Leckman JF: Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013;37(6):1162-1171. 23099282 10.1016/j.neubiorev.2012.09.008 3674207 F1000 Recommendation
38. Wenzel C Kleimann A Bokemeyer S: Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32(4):548-550. 22722499 10.1097/JCP.0b013e31825ac2cb
39. Yoo HK Joung YS Lee JS: A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013;74(8):e772-80. 24021518 10.4088/JCP.12m08189
40. Zheng W Li XB Xiang YQ: Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis. Hum Psychopharmacol. 2016;31(1):11-8. 26310194 10.1002/hup.2498
41. PeÑa MS Yaltho TC Jankovic J: Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147-152. 20818603 10.1002/mds.23402
42. Gilbert DL Budman CL Singer HS: A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37(1):26-30. 24434529 10.1097/WNF.0000000000000017 F1000 Recommendation
43. Kenney C Hunter C Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-197. 17133512 10.1002/mds.21222
44. Chen JJ Ondo WG Dashtipour K: Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):1487-1504. 22749259 10.1016/j.clinthera.2012.06.010
45. Porta M Sassi M Cavallazzi M: Tourette's syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28(7):443-459. 18544005 10.2165/00044011-200828070-00006 F1000 Recommendation
46. Kenney C Hunter C Mejia N: Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259-264. 16960470 10.1097/01.WNF.0000228369.25593.35
47. Jankovic J Clarence-Smith K: Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509-1523. 22014129 10.1586/ern.11.149
48. Cavanna AE Nani A: Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol. 2013;112:373-389. 24295627 10.1016/B978-0-12-411546-0.00012-3
49. Yang CS Zhang LL Zeng LN: Topiramate for Tourette's syndrome in children: a meta-analysis. Pediatr Neurol. 2013;49(5):344-350. 24139534 10.1016/j.pediatrneurol.2013.05.002
50. Jankovic J Jimenez-Shahed J Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70-73. 19726418 10.1136/jnnp.2009.185348 F1000 Recommendation
51. Persaud R Garas G Silva S: An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4(2):10. 23476731 10.1177/2042533312472115 3591685 F1000 Recommendation
52. Kwak CH Hanna PA Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57(8):1190-1193. 10927800 10.1001/archneur.57.8.1190
53. Marras C Andrews D Sime E: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56(5):605-610. 11245710 10.1212/WNL.56.5.605 F1000 Recommendation
54. Porta M Maggioni G Ottaviani F: Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci. 2004;24(6):420-423. 14767691 10.1007/s10072-003-0201-4 F1000 Recommendation
55. Cheung MY Shahed J Jankovic J: Malignant Tourette syndrome. Mov Disord. 2007;22(12):1743-1750. 17566119 10.1002/mds.21599
56. Whiting PF Wolff RF Deshpande S: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473. 26103030 10.1001/jama.2015.6358
57. Müller-Vahl KR: Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013;27(1):119-124. 23187140 10.3233/BEN-120276
58. Kluger B Triolo P Jones W: The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-327. 25649017 10.1002/mds.26142 4357541
59. Curtis A Clarke CE Rickards HE: Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev. 2009; (4):CD006565. 19821373 10.1002/14651858.CD006565.pub2 F1000 Recommendation
60. Piacentini J Woods DW Scahill L: Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929-1937. 20483969 10.1001/jama.2010.607 2993317 F1000 Recommendation
61. Wilhelm S Peterson AL Piacentini J: Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69(8):795-803. 22868933 10.1001/archgenpsychiatry.2011.1528 3772729 F1000 Recommendation
62. McGuire JF Piacentini J Brennan EA: A meta-analysis of behavior therapy for Tourette Syndrome. J Psychiatr Res. 2014;50:106-112. 24398255 10.1016/j.jpsychires.2013.12.009 F1000 Recommendation
63. Scahill L Woods DW Himle MB: Current controversies on the role of behavior therapy in Tourette syndrome. Mov Disord. 2013;28(9):1179-1183. 23681719 10.1002/mds.25488 4283569
64. Zhang JG Ge Y Stead M: Long-term outcome of globus pallidus internus deep brain stimulation in patients with Tourette syndrome. Mayo Clin Proc. 2014;89(11):1506-1514. 25444487 10.1016/j.mayocp.2014.05.019 F1000 Recommendation
65. Servello D Zekaj E Saleh C: Deep Brain Stimulation in Gilles de la Tourette Syndrome: What Does the Future Hold? A Cohort of 48 Patients. Neurosurgery. 2016;78(1):91-100. 26348012 10.1227/NEU.0000000000001004 F1000 Recommendation
66. Kefalopoulou Z Zrinzo L Jahanshahi M: Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurol. 2015;14(6):595-605. 25882029 10.1016/S1474-4422(15)00008-3 F1000 Recommendation
67. Fraint A Pal G: Deep Brain Stimulation in Tourette's Syndrome. Front Neurol. 2015;6:170. 26300844 10.3389/fneur.2015.00170 4523794
68. Servello D Sassi M Gaeta M: Tourette syndrome (TS) bears a higher rate of inflammatory complications at the implanted hardware in deep brain stimulation (DBS). Acta Neurochir (Wien). 2011;153(3):629-632. 21052744 10.1007/s00701-010-0851-y
69. Okun MS Foote KD Wu SS: A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013;70(1):85-94. 23044532 10.1001/jamaneurol.2013.580 F1000 Recommendation
70. Almeida L Martinez-Ramirez D Rossi PJ: Chasing tics in the human brain: development of open, scheduled and closed loop responsive approaches to deep brain stimulation for Tourette syndrome. J Clin Neurol. 2015;11(2):122-131. 25851890 10.3988/jcn.2015.11.2.122 4387477
71. Schrock LE Mink JW Woods DW: Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30(4):448-471. 25476818 10.1002/mds.26094
72. Viswanathan A Jimenez-Shahed J Baizabal Carvallo JF: Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012;90(4):213-224. 22699684 10.1159/000337776
73. Jimenez-Shahed J: Design challenges for stimulation trials of Tourette's syndrome. Lancet Neurol. 2015;14(6):563-565. 25882028 10.1016/S1474-4422(15)00043-5
74. Gilbert DL Jankovic J: Pharmacological treatment of Tourette syndrome. J Obsessive Compuls Relat Disord. 2014;3(4):407-414. 10.1016/j.jocrd.2014.04.006